Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations

Neurochemistry International

Volumn 61, Issue 6, 2012, Pages 866-873

  Adler, Michael ^a,b   Deshpande, Sharad S ^a   Apland, James P ^a   Murray, Bridget ^a   Borrell, Andrew ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

3,4 Diaminopyridine; Acetylcholine; Aminopyridine; Bioterrorism; Botulinum neurotoxin; Calcium channel agonist; Diaphragm muscle; Mouse; Potassium channel blocker; Roscovitine

Indexed keywords

3,4 DIAMINOPYRIDINE; BOTULINUM TOXIN A; ROSCOVITINE;

ANIMAL MODEL; ANIMAL TISSUE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HEMIDIAPHRAGM; INTOXICATION; MOTONEURON; MOUSE; MUSCLE RELAXATION; MUSCLE TETANIC CONTRACTION; MUSCLE TONE; MUSCLE TWITCH; NONHUMAN; PARALYSIS; PHRENIC NERVE; PRIORITY JOURNAL; TIME;

4-AMINOPYRIDINE; ANIMALS; BOTULINUM TOXINS, TYPE A; DIAPHRAGM; MALE; MICE; PARALYSIS; PHRENIC NERVE; PURINES;

CLOSTRIDIUM;

EID: 84868201566     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.07.015     Document Type: Conference Paper

References (60)

1. M. Adler, B. Capacio, and S.S. Deshpande Antagonism of botulinum toxin A-mediated muscle paralysis by 3,4-diaminopyridine delivered via osmotic minipumps Toxicon 38 2000 1381-1388
2. M. Adler, D.A. MacDonald, L.C. Sellin, and G.W. Parker Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin Toxicon 34 1996 237 249
3. M. Adler, and J.D. Nicholson Evaluation of toosendanin as a botulinum neurotoxin antagonist The Botulinum J. 1 2008 208 218
4. M. Adler, A.C. Oliveira, E.X. Albuquerque, N.A. Mansour, and A.T. Eldefrawi Reaction of tetraethylammonium with the open and closed conformation of the acetylcholine receptor ionic channel complex J. Gen. Physiol. 74 1979 129 152
5. M. Adler, J. Scovill, G. Parker, F.J. Lebeda, J. Piotrowski, and S.S. Deshpande Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations Toxicon 33 1995 527 537
6. M.L. Aisen, D. Sevilla, G. Gibson, H. Kutt, A. Blau, L. Edelstein, J. Hatch, and J. Blass 3,4-Diaminopyridine as a treatment for amyotrophic lateral sclerosis J. Neurol. Sci. 129 1995 21 24
7. I.T. Aldoss, T. Tashi, and A.K. Ganti Seliciclib in malignancies Expert Opin. Invest. Drugs 18 2009 1957 1965
8. S.S. Arnon, R. Schechter, T.V. Inglesby, D.A. Henderson, J.G. Bartlett, M.S. Ascher, E. Eitzen, A.D. Fine, J. Hauer, M. Layton, S. Lillibridge, M.T. Osterholm, T. O'Toole, G. Parker, T.M. Perl, P.K. Russell, D.L. Swerdlow, and K. Tonat Botulinum toxin as a biological weapon: medical and public health management JAMA 285 2001 1059 1070
9. C. Benson, J. White, J. De Bono, A. O'Donnell, F. Raynaud, C. Cruickshank, H. McGrath, M. Walton, P. Workman, S. Kaye, J. Cassidy, A. Gianella-Borradori, I. Judson, and C. Twelves A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days Br. J. Cancer 96 2007 29 37
10. M.A. Benson, Z. Fu, J.-J.P. Kim, and M.R. Baldwin Unique ganglioside recognition strategies for clostridial neurotoxins J. Biol. Chem. 286 2011 34015 34022
11. C.T. Bever Jr.; J. Leslie, D.L. Camenga, H.S. Panitch, and K.P. Johnson Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis Ann. Neurol. 27 1990 421 427
12. Z. Buraei, M. Anghelescu, and K.S. Elmslie Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine Biophys. J. 89 2005 1681 1691
13. Z. Buraei, G. Schofield, and K.S. Elmslie Roscovitine differentially affects CaV2 and Kv channels by binding to the open state Neuropharmacology 52 2007 883 894
14. M. Cherington, and D.W. Ryan Botulism and guanidine N. Engl. J. Med. 278 1968 931 933
15. M. Cherington, and D. Schultz Effect of guanidine, germine and steroids in a case of botulism Clin. Toxicol. 11 1977 19 25
16. B.R. DasGupta, and H. Sugiyama A common subunit structure in Clostridium botulinum type A, B and E toxins Biochem. Biophys. Res. Commun. 48 1972 108 112
17. L.E. Davis, J.K. Johnson, J.M. Bicknell, H. Levy, and K.M. McEvoy Human type A botulism and treatment with 3,4-diaminopyridine Electromyogr. Clin. Neurophysiol. 32 1992 379 383
18. I. Delgado-Martínez, R.B. Nehring, and J.B. Sorensen Differential abilities of SNAP-25 homologs to support neuronal function J. Neurosci. 27 2007 9380 9391
19. N.R. DeStefino, A.A. Pilato, M. Dittrich, S.V. Cherry, S. Cho, J.R. Stiles, and S.D. Meriney (R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents Neuroscience 167 2010 838 849
20. M. Dong, F. Yeh, W.H. Tepp, C. Dean, E.A. Johnson, R. Janz, and E.R. Chapman SV2 is the protein receptor for botulinum neurotoxin A Science 312 2006 592 596
21. A. Fischer, and M. Montal Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes J. Biol. Chem. 282 2007 29604 29611
22. S. Gu, S. Rumpel, J. Zhou, J. Strotmeier, H. Bigalke, K. Perry, C.B. Shoemaker, A. Rummel, and R. Jin Botulinum neurotoxin is shielded by NTNHA in an interlocked complex Science 335 2012 977 981
23. I. Guendel, E.T. Agbottah, K. Kehn-Hall, and F. Kashanchi Inhibition of human immunodeficiency virus type-1 by cdk inhibitors Aids Res. Ther. 7 2010 1 14
24. C.L. Hatheway, J.D. Snyder, J.E. Seals, T.A. Edell, and G.E. Lewis Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E J. Infect. Dis. 150 1984 407 412
25. K.C. Hayes Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis Neuropsychiatr. Dis. Treat. 7 2011 229 239
26. + currents in rabbit Schwann cells J. Physiol. (Lond.) 433 1991 183 205
27. J. Kalia, and K.J. Swartz Elucidating the molecular basis of action of a classic drug: guanidine compounds as inhibitors of voltage gated potassium channels Mol. Pharmacol. 80 2011 1085 1095
28. R. Kalla, R. Spiegel, J. Claassen, S. Bardins, A. Hahn, E. Schneider, N. Rettinger, S. Glasauer, T. Brandt, and M. Strupp Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus J. Neuroophthalmol. 31 2011 320 325
29. A.R. Korenke, M.P. Rivey, and D.R. Allington Sustained-release fampridine for symptomatic treatment of multiple sclerosis Ann. Pharmacother. 42 2008 1458 1465
30. L.K. Koriazova, and M. Montal Translocation of botulinum neurotoxin light chain protease through the heavy chain channel Nat. Struct. Biol. 10 2003 13 18
31. R.V. Kukreja, and B.R. Singh Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E Biochemistry 46 2007 14316 14324
32. C. Le Tourneau, S. Faivre, V. Laurence, C. Delbaldo, K. Vera, V. Girre, J. Chiao, S. Armour, S. Frame, S.R. Green, A. Gianella-Borradori, V. Diéras, and E. Raymond Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies Eur. J. Cancer 46 2010 3243 3250
33. B. Li, N.P. Peet, M.M. Butler, J.C. Burnett, D.T. Moir, and T.L. Bowlin Small molecule inhibitors as countermeasures for botulinum intoxication Molecules 16 2010 202 220
34. 2+ channels in mouse motor nerve terminals Eur. J. Neurosci. 9 1997 817 823
35. M. Lindström, and H. Korkeala Laboratory diagnostics of botulism Clin. Microbiol. Rev. 19 2006 298 314
36. H. Lundh, S. Leander, and S. Thesleff Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine J. Neurol. Sci. 32 1977 29 43
37. Marcus, S.M.; 2009. Reflections on the care of a patient severely poisoned by 'rogue' botulinum toxin and rendered paralysed for a protracted hospital stay. The Botululinum J. 1, 318-339.
38. A.V. Mayorov, B. Willis, A. Di Mola, D. Adler, J. Borgia, O. Jackson, J. Wang, Y. Luo, L. Tang, R.J. Knapp, C. Natarajan, M.C. Goodnough, N. Zilberberg, L.L. Simpson, and K.D. Janda Symptomatic relief of botulinum neurotoxin/A intoxication with aminopyridines: a new twist on an old molecule ACS Chem. Biol. 5 2010 1183 1191
39. J. Molgó, M. Lemeignan, and S. Thesleff Aminoglycosides and 3,4-diaminopyridine on neuromuscular block cause by botulinum type A toxin Muscle Nerve 10 1987 464 470
40. J. Molgó, H. Lundh, and S. Thesleff Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes Eur. J. Pharmacol. 61 1980 25 34
41. C. Montecucco, G. Schiavo, and S. Pantano SNARE complexes and neuroexocytosis: how many, how close? Trends Biochem. 30 2005 367 372
42. + channel blocking by aminopyridines Biophys. Chem. 96 2002 1 14
43. Y. Nakamura, and T. Takahashi Developmental changes in potassium currents at the rat calyx of Held presynaptic terminal J. Physiol. (Lond.) 581 2007 1101 1112
44. J.F. Paton Rythmic bursting of pre- and post-inspiratory neurons during central apnoea in mature mice J. Physiol. (Lond.) 502 1997 623 639
45. R. Penner, and F. Dreyer Two different presynaptic calcium currents in mouse motor nerve terminals Pflugers Arch. 406 1986 190 196
46. M. Puggiari, and M. Cherington Botulism and guanidine. Ten years later JAMA 240 1978 2276 2277
47. P.P. Rega, C.E. Bork, K. Burkholder-Allen, M.S. Bisesi, and J.P. Gold Single-breath count test: an important adjunct in the triaging of patients in a mass-casualty incident due to botulism Prehospital Disaster Med. 25 2010 219 222
48. R.F. Robinson, and M.C. Nahata Management of botulism Ann. Pharmacother. 37 2003 127 131
49. G. Ruthel, J.C. Burnett, J.E. Nuss, L.M. Wanner, L.E. Tressler, E. Torres-Melendez, S.J. Sandwick, C.J. Retterer, and S. Bavari Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors Toxins 3 2011 207 217
50. R.L. Shapiro, C. Hatheway, and D.L. Swerdlow Botulism in the United States: a clinical and epidemiological review Ann. Intern. Med. 129 1998 221 228
51. R. Shi, and W. Sun Potassium blockers as an effective treatment to restore impulse conduction in injured axons Neurosci. Bull. 27 2011 36 44
52. L.L. Simpson Identification of the major steps in botulinum toxin action Annu. Rev. Pharmacol. Toxicol. 44 2004 167 193
53. L.L. Simpson A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism Infect. Immun. 52 1986 858 862
54. J. Sobel Botulism Clin. Infect. Dis. 41 2005 1167 1173
55. C.O. Tacket, W.X. Shandera, J.M. Mann, N.T. Hargrett, and P.A. Blake Equine antitoxin use and other factors that predict outcome in type A foodborne botulism Am. J. Med. 76 1984 794 798
56. S. Thesleff Botulinal neurotoxins as tools in studies of synaptic mechanisms Quart. J. Exp. Physiol. 74 1989 1003 1017
57. Tsai, Y.C.; Maditz, R.; Kuo, C.-L.; Fishman, P.S.; Shoemaker, C.B.; Oyler, G.A.; Weissman, A.M.; 2010. Targeting botulinum neurotoxin persistence by the ubiquitin-proteosome system. Proc. Natl. Acad. Sci. USA 107, 16554-16559.
58. T. Vollmer, A.R. Blight, and H.R. Henney 3rd Steady-state pharamacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open label, follow-up study Clin. Ther. 31 2009 2215 2223
59. Z. Yan, P. Chi, J.A. Bibb, T.A. Ryan, and P. Greengard Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons J. Physiol. (Lond.) 540 2002 761 770
60. V. Yarotsky, and K.S. Elmslie Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed state inactivation J. Pharmacol. Exp. Ther. 340 2012 463 472